Ultrasound of Hidradenitis Suppurativa

  • Raffaele Dante Caposiena Caro


Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, debilitating follicular skin disease that usually occurs after puberty. It is associated with painful deep-seated, inflamed lesions commonly in the axillary, inguinal, and anogenital regions and has a great impact on the patient’s quality of life. Physical examination may have low sensitivity to detect and differentiate nodules, abscesses, or fistulous tracts, which are critical data to assess the HS severity. Ultrasound assessment can be considered a reliable and safe imaging noninvasive tool valuable to define better the clinical HS lesions, to improve the staging, and to monitor the response of treatments.


Hidradenitis suppurativa Dermal ultrasound Immunotherapy Sinus tract Biologics Retinoids 


  1. 1.
    Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, editors. Acne and related disorders. London: Martin Dunitz; 1989. p. 345–57.Google Scholar
  3. 3.
    Von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and interfollicular epidermis. Exp Dermatol. 2010;19:533–7.CrossRefGoogle Scholar
  4. 4.
    Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatol Endocrinol. 2010;2:9–16.CrossRefGoogle Scholar
  5. 5.
    Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.PubMedCrossRefGoogle Scholar
  6. 6.
    Thornton JP, Abcarian H. Surgical treatment of perianal and perineal hidradenitis suppurativa. Dis Colon Rectum. 1978;21:573–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Fitzsimmons JS, Guilbert PR. A family study of hidradenitis suppurativa. J Med Genet. 1985;22:367–73.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917–24. Epub 2018 Feb 22.CrossRefPubMedGoogle Scholar
  9. 9.
    Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.PubMedCrossRefGoogle Scholar
  10. 10.
    Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118–22.PubMedCrossRefGoogle Scholar
  13. 13.
    Calao M, Wilson JL, Spelman L, Billot L, Rubel D, Watts AD, Jemec GBE. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PLoS One. 2018;13(7):e0200683. eCollection 2018.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Banerjee A, Mcnish S, Shanmugam VK. Interferon-gamma (IFN-gamma) is elevated in wound exudate from hidradenitis suppurativa. Immunol Invest. 2017;46:149–58. Scholar
  15. 15.
    Ingram JR. The genetics of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):23–8. Scholar
  16. 16.
    Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Starnes TW, Bennin DA, Bing X, Eickhoff JC, Grahf DC, Bellak JM, et al. The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages. Blood. 2014;123:2703–14.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Zeeli T, Padalon-Brauch G, Ellenbogen E, Gat A, Sarig O, Sprecher E. Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. Clin Exp Dermatol. 2015;40:367–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol. 1996;135(5):721–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8–11.PubMedCrossRefGoogle Scholar
  21. 21.
    van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP. Adalimumab [antitumour necrosis factor alpha] treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298–305.PubMedCrossRefGoogle Scholar
  22. 22.
    van der Zee HH, de Ruiter L, Boer J, et al. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol. 2012;166(1):98–106.PubMedCrossRefGoogle Scholar
  23. 23.
    Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176:1588–98. Scholar
  24. 24.
    Di Caprio R, Balato A, Caiazzo G, Lembo S, Raimondo A, Fabbrocini G, et al. IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res. 2017;309:673–8. Scholar
  25. 25.
    Thomi R, Kakeda M, Yawalkar N, Schlapbach C, Hunger RE. Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017;31:2091–6. Scholar
  26. 26.
    Thomi R, Yerly D, Yawalkar N, Simon D, Schlapbach C, Hunger RE. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol. 2017;177:1358–66. Scholar
  27. 27.
    Jimenez-Gallo D, De La Varga-Martinez R, Ossorio-Garcia L, Albarran-Planelles C, Rodriguez C, Linares-Barrios M. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm. 2017;2017:2450401. Scholar
  28. 28.
    Matusiak L, Szczech J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76:670–5. Scholar
  29. 29.
    Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Hessam S, Sand M, Gambichler T, Bechara FG. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2015;73:998–1005. Scholar
  31. 31.
    Ring HC, Bay L, Nilsson M, Kallenbach K, Miller IM, Saunte DM, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol. 2017;176:993–1000. Scholar
  32. 32.
    Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clin Infect Dis. 2017;65:282–91. Scholar
  33. 33.
    Nikolakis G, Liakou AI, Bonovas S, Seltmann H, Bonitsis N, Join-Lambert O, et al. Bacterial colonization in hidradenitis suppurativa/acne inversa: a cross sectional study of 50 patients and review of the literature. Acta Derm Venereol. 2017;97:493–8. Scholar
  34. 34.
    König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198:261–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831–9.CrossRefGoogle Scholar
  36. 36.
    Wiltz O, Schoetz DJ Jr, Murray JJ, Roberts PL, Coller JA, Veidenheimer MC. Perianal hidradenitis suppurativa. The Lahey Clinic experience. Dis Colon Rectum. 1990;33:731–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Freiman A, Bird G, Metelitsa AI, Barankin B, Lauzon GJ. Cutaneous effects of smoking. J Cutan Med Surg. 2004;8:415–23.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Bianchi L, Caposiena Caro RD, Ganzetti G, Molinelli E, Dini V, Oranges T, Romanelli M, Fabbrocini G, Monfrecola G, Napolitano M, Egan CG, Musumeci ML, Lacarrubba F, Micali G, Passoni E, Calzavara-Pinton PG, Venturini M, Zanca A, Offidani AM. Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort. Clin Exp Dermatol. 2019;44:e177–80. [Epub ahead of print]CrossRefPubMedGoogle Scholar
  39. 39.
    Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27–35.PubMedCrossRefGoogle Scholar
  41. 41.
    Nazary M, van der Zee HH, Prens EP, Folkerts G, Boer J. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol. 2011;672(1-3):1–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Romaní J, Agut-Busquet E, Corbacho M, Herrerías-Moreno J, Luelmo J. Body fat composition in hidradenitis suppurativa: a hospital-based cross-sectional study. Int J Dermatol. 2017;56(3):e62–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Boer J, Nazary M, Riis PT. The role of mechanical stress in hidradenitis suppurativa. Dermatol Clin. 2016;34(1):37–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.PubMedCrossRefGoogle Scholar
  45. 45.
    Harrison BJ, Read GF, Hughes LE. Endocrine basis for the clinical presentation of hidradenitis suppurativa. Br J Surg. 1988;75(10):972–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Mengesha YM, Holcombe TC, Hansen RC. Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Pediatr Dermatol. 1999;16(4):292–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Jayasena CN, Comninos AN, Nijher GM, et al. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. J Clin Endocrinol Metab. 2013;98(11):4464–74.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GB. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171(4):819–24.PubMedCrossRefGoogle Scholar
  49. 49.
    Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol. 2014;32(3):397–408.PubMedCrossRefGoogle Scholar
  50. 50.
    Martorell A, Wortsman X, Alfageme F, Roustan G, Arias-Santiago S, Catalano O, Scotto di Santolo M, Zarchi K, Bouer M, Gaitini D, Gonzalez C, Bard R, García-Martínez FJ, Mandava A. Ultrasound evaluation as a complementary test in hidradenitis suppurativa: proposal of a standardized report. Dermatol Surg. 2017;43(8):1065–73.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Wortsman X, Moreno C, Soto R, Arellano J, et al. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg. 2013;39:1835–42.PubMedCrossRefGoogle Scholar
  52. 52.
    Martorell A, Segura Palacios JM. Ultrasound examination of hidradenitis suppurativa. Actas Dermosifiliogr. 2015;106(Suppl 1):49–59.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Lipsker D, Severac F, Freysz M, Sauleau E, Boer J, Emtestam L, Matusiak Ł, Prens E, Velter C, Lenormand C, Meyer N, Jemec GB. The ABC of hidradenitis suppurativa: a validated glossary on how to name lesions. Dermatology. 2016;232(2):137–42.PubMedCrossRefGoogle Scholar
  54. 54.
    Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985–98.PubMedCrossRefGoogle Scholar
  55. 55.
    Lipsker D, Revuz J. Phenotypic characterization of patients with hidradenitis suppurativa. Dermatology. 2016;232(4):521.PubMedCrossRefGoogle Scholar
  56. 56.
    van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73(5 Suppl 1):S23–6.PubMedGoogle Scholar
  57. 57.
    Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44.PubMedCrossRefGoogle Scholar
  58. 58.
    Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729–39.Google Scholar
  59. 59.
    Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211–3.PubMedCrossRefGoogle Scholar
  60. 60.
    Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Chiricozzi A, Faleri S, Franceschini C, Caro RD, Chimenti S, Bianchi L. AISI: a new disease severity assessment tool for hidradenitis suppurativa. Wounds. 2015;27(10):258–64.PubMedGoogle Scholar
  62. 62.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–55.PubMedCrossRefGoogle Scholar
  63. 63.
    Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R, European Hidradenitis Suppurativa Foundation Investigator Group. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434–42.PubMedCrossRefGoogle Scholar
  65. 65.
    Wortsman X, Castro A, Figueroa A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75(4):760–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Caposiena Caro RD, Solivetti FM, Bianchi L. Power Doppler ultrasound assessment of vascularization in hidradenitis suppurativa lesions. J Eur Acad Dermatol Venereol. 2018;32:1360–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019–32.. Review.PubMedCrossRefGoogle Scholar
  68. 68.
    Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1013–27.PubMedCrossRefGoogle Scholar
  69. 69.
    Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61(1):51–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Simonart T. Hidradenitis suppurativa and smoking. J Am Acad Dermatol. 2010;62(1):149–50.PubMedCrossRefGoogle Scholar
  71. 71.
    Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin. 2010;28(4):779–93.PubMedCrossRefGoogle Scholar
  72. 72.
    Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J Am Acad Dermatol. 2012;67(6):1129–35.PubMedCrossRefGoogle Scholar
  73. 73.
    Caposiena Caro RD, Cannizzaro MV, Botti E, Di Raimondo C, Di Matteo E, Gaziano R, Bianchi L. Clindamycin versus clindamycin plus rifampicin in Hidradenitis Suppurativa treatment: clinical and ultrasound observations. J Am Acad Dermatol. 2019;80:1314–21.PubMedCrossRefGoogle Scholar
  74. 74.
    Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343–51.. Review.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Rosi E, Pescitelli L, Ricceri F, Di Cesare A, Novelli A, Pimpinelli N, Prignano F. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa. Dermatol Ther. 2018;5:e12792.Google Scholar
  77. 77.
    Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222:49–58.PubMedCrossRefGoogle Scholar
  78. 78.
    Join-Lambert O, Coignard-Biehler H, Jais JP, Delage M, Guet-Revillet H, Poirée S, Duchatelet S, Jullien V, Hovnanian A, Lortholary O, Nassif X, Nassif A. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71(2):513–20.PubMedCrossRefGoogle Scholar
  79. 79.
    Braunberger TL, Nartker NT, Nicholson CL, Nahhas AF, Parks-Miller A, Hanna Z, Jayaprakash R, Ramesh MS, Rambhatla PV, Hamzavi IH. Ertapenem—a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa. Int J Dermatol. 2018;57(9):1088–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Mendes-Bastos P, Martorell A, Magina S. Ertapenem for the treatment of Hidradenitis suppurativa: how much do we need it? Actas Dermosifiliogr. 2018;109(7):582–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Chahine AA, Nahhas AF, Braunberger TL, Rambhatla PV, Hamzavi IH. Ertapenem rescue therapy in hidradenitis suppurativa. JAAD Case Rep. 2018;4(5):482–3.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Albrecht J, Baine PA, Ladizinski B, Jemec GB, Bigby M. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A critically appraised topic. Br J Dermatol. 2019;180:749–55.PubMedCrossRefGoogle Scholar
  83. 83.
    Andersen RK, Jemec GB. Treatments for hidradenitis suppurativa. Clin Dermatol. 2017;35(2):218–24.PubMedCrossRefGoogle Scholar
  84. 84.
    Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–34.PubMedCrossRefGoogle Scholar
  85. 85.
    Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80:60–69.e2.PubMedCrossRefGoogle Scholar
  86. 86.
    Kimball AB, Sundaram M, Shields AL, Hudgens S, Okun M, Foley C, Ganguli A. Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018;79:1141–3.PubMedCrossRefGoogle Scholar
  87. 87.
    Caposiena Caro RD, Cannizzaro MV, Di Raimondo C, Di Matteo E, Botti E, Rossi P, Bianchi L. Long-term efficacy and safety of adalimumab on a severe case of Hidradenitis Suppurativa. G Ital Dermatol Venereol. 2018;
  88. 88.
    Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80–8. Epub 2018 Jul 3.CrossRefPubMedGoogle Scholar
  89. 89.
  90. 90.
    Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40(1):73–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164(1):170–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218(2):134–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Danby FW. Night blindness, vitamin A deficiency, and isotretinoin psychotoxicity. Dermatol Online J. 2003;9(5):30.PubMedGoogle Scholar
  94. 94.
    Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115(3):263–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat. 2005;16(2):75–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Lee A, Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol. 2015;56(3):192–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Raffaele Dante Caposiena Caro
    • 1
  1. 1.Department of Systems MedicineUniversity of Rome, Tor VergataRomeItaly

Personalised recommendations